Hertin und Partner Rechts- und Patentanwälte PartG mbB

In a first aspect, the invention relates to a computer-implemented method for supporting a treatment of a cancer patient. The patient is provided with information about cancer treatment and related guidelines. During the treatment process, patient data is collected through a module via a user interface. This data is then pseudonymized to ensure privacy and stored on a server. The stored data is subsequently analysed, and based on this analysis, a treatment recommendation is provided at the user interface to assist in the patient's ongoing treatment. In a further aspect, the invention relates to a computer program product.

The invention of the current application is directed a method and system for destruction of aqueous recalcitrant organic concentrates and fluorinated organic concentrates including aqueous film forming foam (AFFF) fire retardants and high concentrations of perfluoroalkyl and polyfluoroalkyl Substances (PFAS) such as foamate, backwash, still bottoms, filtration reject, and organic-AFFF matrix ancillary waste streams, are generally carried out by high temperature incineration. The method and system including mixing a potassium hydroxide (KOH) electrolyte stream from a KOH electrolyte tank and an aqueous concentrate feed to form an anolyte, mineralizing the anolyte in an anode compartment of an electrolytic mineralization unit to form a treated anolyte, and producing an electrolyzed KOH electrolyte from a KOH electrolyte stream which is fed into a cathode compartment of the electrolytic mineralization unit.

The invention relates to a gradient reactor for generating a concentration gradient, comprising: a) a first layer comprising i) at least one fluid inlet for an injection of at least one fluid, ii) at least one dilutant inlet for an injection of a dilutant, and iii) at least one outlet for an ejection of the at least one fluid, b) a second layer, c) a third layer suitable for culturing microorganisms or cells, wherein a concentration gradient is formable in the second layer, and the concentration gradient is transferable from the second layer to the third layer. The invention further relates to a system comprising i) the gradient reactor according to any one of the preceding claims, wherein the gradient reactor optionally further comprises pumps, preferably micropumps, for automated injection of the at least one fluid and the dilutant, ii) a camera system, and iii) a computer program comprising instructions, optionally wherein the instructions, when the program is executed by a computer, cause the computer to analyze the growth, proliferation and/or survival of the microorganisms or cells. The invention also relates to the use of the gradient reactor according to any one of the preceding claims, for the generation of overlapping stationary or dynamic concentration gradients, for analyzing the efficacy or effect of different biologically active compounds, for assessing possible combinatory therapies, for assessing the probability of future resistance to the different biologically active compounds, or for analyzing pharmacokinetics. The invention also relates to a method for generating one or more concentration gradients, comprising: i) providing a gradient reactor according to the invention, or a system according to the invention, ii) simultaneously injecting the dilutant and the at least one fluid, into the at least one dilutant inlet and the at least one fluid inlet, respectively, iii) generating one or more concentration gradients in the second layer, iv) wherein the one or more concentration gradients transfer from the second layer to the third layer, wherein the third layer is suitable for culturing microorganisms or cells.

Die Erfindung betrifft ein Deckenelement für eine Gebäudedecke. Das Deckenelement ist als Holz-Beton-Verbund ausgebildet. Das Deckenelement umfasst ein Holzbauteil aufweisend eine oder mehrere Formstrukturen, ein Betonbauteil umfassend eine Elementdecke und eine Ortbetonergänzung, einen Gitterträger, ein Verbindungsmittel und eine Hülse. Das Verbindungsmittel ist in die Hülse eingebracht. Das Betonbauteil ist mit dem Holzbauteil über das Verbindungsmittel und/oder die Formstruktur verbunden. Weiterhin betrifft die Erfindung ein Verfahren zur Herstellung des Deckenelementes.

The invention relates to a system for storage and production of electrical energy, wherein electrical energy is converted to thermal energy for storage, and thermal energy is converted to electrical energy for production. CO<2> is stored temporarily and/or permanently in a geological formation. The system comprises a surface portion and a subsurface portion. The subsurface portion comprises at least one underground reservoir, which is configured for temporary and/or permanent CO<2> storage. It has at least one caprock layer positioned above the reservoir and at least one well in communication with the at least one reservoir and the surface portion. The surface portion comprises a charging cycle, which is configured for storage of electrical energy, a discharging cycle, which is configured for production of electrical energy, and means for thermal energy storage. The subsurface portion and the surface portion are in communication with each other via a working fluid.

The invention relates to a matrix configured for use in an extracorporeal blood treatment device, wherein the matrix comprises a solid substrate, to which an agent is immobilized, wherein said agent specifically binds mitochondrial DNA (mtDNA) in the blood or blood plasma of a subject. The invention also relates to methods for preparing the matrix according to the present invention, wherein the oligonucleotide and/or the polypeptide is immobilized on the solid substrate of the matrix by covalent coupling, preferably by crosslinking. The invention further relates to a blood treatment device configured to remove mtDNA from the blood or blood plasma of a person in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix according to the present invention. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device according to the present invention, wherein the extracorporeal blood circuit comprises means for transporting blood or blood plasma from a patient's vascular system to the blood treatment device at a defined flow rate and means for returning the treated blood or blood plasma back to the patient.

The invention relates to a medical product for preventing or correcting selenium deficiency in a patient comprising a solution provided in a flexible container comprising at least one selenium compound in the form of Se(IV), characterized in that the solution comprises dissolved oxygen (DO).

Die Erfindung betrifft ein Verfahren zur Herstellung einer nicht-flüssigen Mahlerzeugnis-Zusammensetzung für die Herstellung einer flüssigen Mahlerzeugnis-Zusammensetzung, umfassend (i.) Bereitstellen einer Paste enthaltend ein Mahlerzeugnis, Wasser und ein Pflanzenfett, wobei die Paste 5 bis 50 Gew.-% Wasser und 2 bis 10 Gew.-% Pflanzenfett enthält, bezogen auf das Gesamtgewicht der Paste, (ii.) Formen der Paste (i.) zu einem Strang. In einem weiteren Aspekt betrifft die Erfindung eine Mahlerzeugnis-Zusammensetzung zur Auflösung und/oder Dispergierung in einer verzehrbaren Flüssigkeit hergestellt und/oder herstellbar mittels des Verfahrens der vorliegenden Erfindung, dadurch gekennzeichnet, dass die Mahlerzeugnis-Zusammensetzung 5 bis 15 Gew.-% Wasser und 2 bis 10 Gew.-% Pflanzenfett enthält. In einem weiteren Aspekt betrifft die Erfindung eine Lebensmittel-Zusammensetzung zur Auflösung und/oder Dispergierung in einer verzehrbaren Flüssigkeit enthaltend eine Mahlerzeugnis-Zusammensetzung hergestellt und/oder herstellbar mittels des Verfahrens der vorliegenden Erfindung. In einem weiteren Aspekt betrifft die Erfindung eine flüssige Mahlerzeugnis-Zusammensetzung hergestellt durch Auflösen und/oder Dispergieren der Mahlerzeugnis-Zusammensetzung der vorliegenden Erfindung in einer verzehrbaren Flüssigkeit.

The invention relates to a method for analyzing a sample comprising one or more molecules of interest by a mass spectrometer, comprising ionizing a multitude of molecules and/or fragments thereof comprised within a sample to obtain a multitude of molecule ions (source ions), and performing mass spectrometry (MS) analysis comprising a. analyzing the molecule ions and/or fragments thereof in a MS1 measurement, thereby acquiring ion mass spectral data of at least a fraction of the molecule ions and/or fragments thereof (source ions) comprising their mass to charge ratio (m/z), b./c. isolating a first fraction and a second of the molecule ions (precursor ions) having a m/z within a first m/z range (mz1; isolation window) and a second m/z range (mz2; isolation window), using a mass filter device, wherein the first m/z range is selected based on the ion mass spectral data acquired in step a. or one or more iterations of step a. and/or e., and wherein the second m/z range (mz2) overlaps with the first m/z range (mz1), d. fragmenting at least a fraction of the molecule ions (precursor ions) isolated in steps b. and c., separately, to obtain a multitude of biomolecule fragment ions from each of the respective fragmented molecule ions (precursor ions), and e. analyzing the multitude of biomolecule fragment ions in one or more MS2 measurement, thereby acquiring ion mass spectral data of the analyzed biomolecule fragment ions.

The invention relates to a blood treatment device configured to dephosphorylate extracellular adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP) and/or lipopolysaccharide (LPS) in the blood of a patient in need thereof in an extracorporeal blood circuit, wherein the device comprises a matrix having alkaline phosphatase (AP) immobilized thereon. The invention further relates to an extracorporeal blood circuit comprising a blood treatment device of the invention and to the blood treatment device for use as a medicament or to methods of treating an infection, preferably a blood or systemic infection, such as sepsis, and/or for the treatment of sepsis-associated acute kidney injury (AKI).